Iizuka Yukihiko

Homepage URL (1)： http://kaken.nii.ac.jp/ja/r/00365404

Research keywords (17)：好中球性炎症疾患 , 気管支拡張症 , 肺NTM症 , Regenerative medicine , Fracture liaison service , Secondary fracture prevention , Fragility fracture , Neuro-immunology , Neuro-degenerative diseases , Maltiple Sclerosis , Parkinson's Disease , Fragile X Syndrome , 発達障害 , Dysbindin , Psychiatry diseases , DISC1 , Schizophrenia

Research theme for competitive and other funds (2)：

2011 - 2012 Analysis for mechanisms of neurotransmitter transport via Dysbindin
2004 - 2005 Identification of T cell epitope peptides derived from glioma antigens

Papers (29)：

Hiroshi Hagino, Nobuaki Kawakami, Yukihiko Iizuka. An internet survey of orthopedic surgeons and healthcare professionals on fracture liaison service. The Journal of Japan Osteoporosis Society. 2021. 7. 2. 49-59
横山和正, 佐藤竜介, 牧岡大器, 飯塚幸彦, 長谷昌知, Yan Ling, 鳥居慎一, 齋田孝彦. 背景因子別にみたナタリズマブの日本人多発性硬化症に対する有効性ナタリズマブ使用成績調査中間解析から(第二報). 診療と新薬. 2018. 55. 6. 449-456
Takahiko Saida, Kazumasa Yokoyama, Ryusuke Sato, Haruki Makioka, Yukihiko Iizuka, Masakazu Hase, Yan Ling, Shinichi Torii. Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan. Neurology and Therapy. 2017. 6. 2. 197-211
飯塚幸彦, 宮城島久海, 笹島隆義. 治療抵抗性統合失調症患者を対象としたclozapineの製造販売後調査結果(中間集計). 臨床精神薬理. 2016. 19. 6. 859-876
Daisuke Tsuboi, Keisuke Kuroda, Motoki Tanaka, Takashi Namba, Yukihiko Iizuka, Shinichiro Taya, Tomoyasu Shinoda, Takao Hikita, Shinsuke Muraoka, Michiro Iizuka, et al. Disrupted-in-schizophrenia 1 regulates transport of ITPR1 mRNA for synaptic plasticity. NATURE NEUROSCIENCE. 2015. 18. 5. 698-+

ｍore...

MISC (41)：

斎田孝彦, 横山和正, 佐藤竜介, 牧岡大器, 飯塚幸彦, 杉山奈未, 松田尚人, 鳥居慎一. ナタリズマブの安全性と有効性:製造販売後調査4年目の中間解析結果. 日本神経学会学術大会プログラム・抄録集. 2019. 60th. 434
横山和正, 佐藤竜介, 牧岡大器, 飯塚幸彦, 平松且稔, Yan Ling, 鳥居慎一, 齋田孝彦. Safety and Effectiveness of Natalizumab Post-Marketing Surveillance: The 3rd Year Interim Results(和訳中). 神経免疫学. 2018. 23. 1. 132-132
齋田孝彦, 佐藤竜介, 牧岡大器, 飯塚幸彦, 平松且稔, Yan Ling, 鳥居慎一, 横山和正. Natalizumab Post-Marketing Surveillance: Stratified Interim Analysis with Anti-JCV Antibody Status(和訳中). 神経免疫学. 2018. 23. 1. 136-136
横山和正, 佐藤竜介, 牧岡大器, 飯塚幸彦, 平松且稔, Yan Ling, 鳥居慎一, 齋田孝彦. ナタリズマブの安全性と有効性に関する市販後調査研究 3年目の中間結果(Safety and Effectiveness of Natalizumab Post-Marketing Surveillance: The 3rd Year Interim Results). 神経免疫学. 2018. 23. 1. 132-132
齋田孝彦, 佐藤竜介, 牧岡大器, 飯塚幸彦, 平松且稔, Yan Ling, 鳥居慎一, 横山和正. Natalizumabの市販後調査研究抗JCV抗体の状況に関する層別化中間分析結果(Natalizumab Post-Marketing Surveillance: Stratified Interim Analysis with Anti-JCV Antibody Status). 神経免疫学. 2018. 23. 1. 136-136

ｍore...

Patents (4)：

Lectures and oral presentations (1)：

治療抵抗性統合失調症治療薬クロザピンの市販後全例調査の中間報告
(精神神経学雑誌 2015)

Professional career (1)：

博士(医学) (慶應義塾大学)

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page